2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Molecular Testing, Newborn Screening, Omics Technologies, Pathology, Serologic Tests, Bioinformatics, Computational Biology, Emerging Technologies, Profiling, Treatment Considerations, Combination Therapy, Therapy Sequence, Biological Therapies, Antibody Therapy, Transplantation, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Surgical, Adverse Events, Artificial Intelligence (AI), Computer Vision, Deep Learning, Generative AI, Machine Learning, Natural Language Processing, Biological Processes, Pathogenesis, CHIP, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Clinical Guidelines, Diseases, Hemoglobinopathies, Sickle Cell Disease, Immunology, GVHD, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, CLL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, AML, APL, Translational Research, MDS, MPN, CMML, Clinical Research, Clinical Trials, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Pediatric
PAPER

6110 Defining key features of amplification-free Cas13 detection of HBB RNA for sickle cell disease diagnostics

Amelia Seabold, Alina Luchyshyn2, Hannah Chae3, Hojun Li, MD,PhD4, Feng Zhang, PhD5
1 University of Oxford, Oxford, United Kingdom
2 Harvard-MIT Program in Health Sciences and Technology, Harvard Medical School, Boston, United States
3 University of California San Diego, La Jolla, California, United States
4 Rady Children's, San Diego, California, United States, University of California San Diego, La Jolla, California, United States
5 Broad Institute of MIT & Harvard, Cambridge, Massachusetts, United States

Over 500,000 infants are born with sickle cell disease (SCD) each year, with 90% of them in low- and middle-income countries that lack comprehensive newborn screening programs. Early diagnosis and follow-up care consisting of vaccinations, antibiotic prophylaxis, and timely interventions markedly decrease under-5 mortality. Thus, the need for inexpensive, rapid, easy-to-use, point-of-care molecular diagnostics for SCD has never been greater.

In this study, we define key biochemical and operational features governing amplification-free Cas13-based direct detection of human HBB RNA and show that endogenous HBB mRNA can be detected in RNA isolated from whole blood using a field-compatible workflow. We also demonstrate these findings in BCR:ABL RNA, showing that the identified principles are not specific to HBB.

By titrating target HBB RNA copies using a LwaCas13a (Leptotrichia wadei, hereon Cas13) fluorescent reporter assay, we show there is target-dependent fluorescence across inputs from 3x109 to 3x1012 copies of HBB per reaction. Signal intensity peaks between 2x1010 and 2x1011 copies and declines at higher target concentrations. BCR:ABL RNA demonstrated a similar saturation pattern beyond optimal target concentration. We further establish that Cas13 can rapidly detect synthetic HBB and BCR:ABL RNA targets in less than 10 minutes with tolerance of reaction volumes between 100-1000uL and temperatures between 15-32 °C (HBB) and 4-42 °C (BCR:ABL).

We additionally identify two major barriers to endogenous mRNA target detection in whole blood: interference from non-target RNA and limited accessibility of the target sequence within folded full-length HBB transcripts. Using RNA from 293T cells as non-target interference, we show that increasing non-target RNA while holding all other reagents constant progressively decreases target signal, with no detectable signal at the native target to non-target ratio. Greater tolerance of non-target RNA when there is less total RNA in the system suggests that the limiting factor is the ratio of non-target RNA to Cas13 and CRISPR RNA (crRNA), rather than the ratio of non-target to target RNA. We demonstrate partial resolution of this issue by increasing Cas13 enzyme (80-fold) and crRNA (100-fold) and enriching target RNA using bead-based capture.

To improve target accessibility, we tested small-molecule additives that destabilize RNA secondary structure and found that betaine consistently alleviated RNA-folding-associated inhibition across a broad concentration range. A 5-minute treatment with 0.15 M potassium hydroxide (KOH) to hydrolyze RNA into fragments improved target accessibility and enhanced bead-mediated enrichment of target RNA. Sequential KOH and betaine treatments of whole blood RNA produced a substantial HBB signal even in the absence of sequence-specific capture probes, suggesting that alkaline-hydrolyzed RNA fragments can non-specifically bind to streptavidin beads at levels sufficient to support downstream detection.

Finally, to assess whether bead-based precipitation could be performed without centrifugation (unavailable in the field at the point-of-care), we developed a column to enable bead capture and wash steps under manual syringe-driven flow. This approach produced a detectable signal above the limit of quantification, demonstrating that target enrichment can be achieved without specialized laboratory instrumentation. Our results suggest that neither amplification, sequence-specific probes, nor centrifugation is essential. While this RNA target detection chemistry is compatible with low-cost point-of-care deployment, upstream whole-blood RNA isolation remains a barrier to a fully field-deployable assay.

Our work provides a starting framework for rational design of amplification-free Cas13 diagnostics for human genetic disease testing in the field, which could transform diagnostic capability in resource-constrained settings. Our data indicate that successful assay design must account for at least three factors simultaneously: target copy-number operating range, inhibition from non-target RNA, and structural accessibility of the full-length target transcript. For HBB detection, increasing Cas13 and crRNA concentrations, improving target accessibility through mild alkaline hydrolysis and betaine treatment, and enriching for the target through probe-assisted capture collectively enabled direct amplification-free detection of HBB in RNA isolated from whole blood.

Amelia Seabold: No relevant conflicts of interest to declare.